相关实验视频
Updated: Sep 13, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.1K
胆固醇对2型糖尿病患者血小板聚合的影响:来自随机选的安慰剂控制试验的结果
Jonathan M Baier1, Kristian L Funck2, Liv Vernstrøm3
1Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark; Dept. of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Journal of diabetes and its complications
|July 27, 2025
概括
低剂量胆固醇在2型糖尿病患者中没有影响血小板聚合. 这些发现表明,科尔奇辛.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 糖尿病学 糖尿病学
背景情况:
- 2型糖尿病增加了心血管疾病 (CVD) 的风险,部分原因是血小板活性升高.
- 科尔奇辛是一种抗炎药物,具有降低心血管事件的潜力.
- 它对糖尿病血小板功能的影响需要澄清.
研究的目的:
- 为了评估低剂量胆固醇对血小板聚合的影响.
- 评估2型糖尿病患者血小板激活指数的变化.
- 为了确定胆固醇的心脏保护作用是否涉及直接的血小板调节.
主要方法:
- 一个26周,双盲,随机,安慰剂对照试验.
- 100名患有2型糖尿病和心血管疾病风险因素的参与者接受了胆固醇 (0.5毫克/天) 或安慰剂.
- 血小板聚合通过使用ADP,AA和TRAP激动剂的聚合计进行评估.
主要成果:
- 在胆固醇和安慰剂组之间,ADP,AA或TRAP诱导的血小板聚合没有显著差异.
- 血小板数,平均血小板体积和不成熟的血小板分数保持不变.
- 95名参与者完成了试验,没有关于血小板功能的重大不良事件报告.
结论:
- 低剂量的胆固醇在2型糖尿病中不会显著改变血小板聚合或激活.
- 在这种人群中,素的心脏保护作用可能不会通过直接影响血小板功能来介导.
- 需要进一步的研究来阐明菌素在糖尿病中心血管保护作用背后的机制.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
646
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
646
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
263
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
263
Oral Hypoglycemic Agents: Biguanides and Glitazones
304
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
304
Dipeptidyl Peptidase 4 Inhibitors
261
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
261
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K

